ARCA Biopharma in Reverse Merger Pact With Oruka Therapeutics

Dow Jones

Apr 03, 2024

By Colin Kellaher

ARCA biopharma has struck a deal to combine with privately held biotechnology company Oruka Therapeutics in an all-stock reverse merger.

ARCA on Wednesday said its shareholders would own about 2.38% of the combined company, while Oruka investors would own roughly 97.6%.

ARCA, based in Westminster, Colo., said it also expects to pay a dividend of about $20 million to its shareholders immediately prior to the closing of the deal, slated for the third quarter.

A reverse merger allows a private company to go public by merging with a public one at a lower cost than is involved in traditional initial public offerings.

ARCA said the combined company, which will operate under the Oruka Therapeutics name and trade under the symbol ORKA, will focus on advancing Oruka's portfolio of biologics targeting chronic skin diseases.

ARCA said Oruka has struck a deal for a pre-closing private financing of around $275 million that would give the combined company a runway to fund its operations through 2027.

Trading in shares of ARCA, which closed Tuesday at $1.71, was halted premarket on Wednesday.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

April 03, 2024 07:44 ET (11:44 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2424781991"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2424781991\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2424781991?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-03 19:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2424781991","market":"sg","top_or_hot":-1,"title":"ARCA Biopharma in Reverse Merger Pact With Oruka Therapeutics","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  ARCA biopharma has struck a deal to combine with privately held biotechnology company Oruka <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> in an all-stock reverse merger. \n</p>\n<p>\n  ARCA on Wednesday said its shareholders would own about 2.38% of the combined company, while Oruka investors would own roughly 97.6%. \n</p>\n<p>\n  ARCA, based in Westminster, Colo., said it also expects to pay a dividend of about $20 million to its shareholders  immediately prior to the closing of the deal, slated for the third quarter. \n</p>\n<p>\n  A reverse merger allows a private company to go public by merging with a public one at a lower cost than is involved in traditional initial public offerings. \n</p>\n<p>\n  ARCA said the combined company, which will operate under the Oruka Therapeutics name and trade under the symbol ORKA, will focus on advancing Oruka's portfolio of biologics targeting chronic skin diseases. \n</p>\n<p>\n  ARCA said Oruka has struck a deal for a pre-closing private financing of around $275 million that would give the combined company a runway to fund its operations through 2027. \n</p>\n<p>\n  Trading in shares of ARCA, which closed Tuesday at $1.71, was halted premarket on Wednesday. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 03, 2024 07:44 ET (11:44 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ARCA Biopharma in Reverse Merger Pact With Oruka Therapeutics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nARCA Biopharma in Reverse Merger Pact With Oruka Therapeutics\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-04-03 19:44</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  ARCA biopharma has struck a deal to combine with privately held biotechnology company Oruka <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> in an all-stock reverse merger. \n</p>\n<p>\n  ARCA on Wednesday said its shareholders would own about 2.38% of the combined company, while Oruka investors would own roughly 97.6%. \n</p>\n<p>\n  ARCA, based in Westminster, Colo., said it also expects to pay a dividend of about $20 million to its shareholders  immediately prior to the closing of the deal, slated for the third quarter. \n</p>\n<p>\n  A reverse merger allows a private company to go public by merging with a public one at a lower cost than is involved in traditional initial public offerings. \n</p>\n<p>\n  ARCA said the combined company, which will operate under the Oruka Therapeutics name and trade under the symbol ORKA, will focus on advancing Oruka's portfolio of biologics targeting chronic skin diseases. \n</p>\n<p>\n  ARCA said Oruka has struck a deal for a pre-closing private financing of around $275 million that would give the combined company a runway to fund its operations through 2027. \n</p>\n<p>\n  Trading in shares of ARCA, which closed Tuesday at $1.71, was halted premarket on Wednesday. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 03, 2024 07:44 ET (11:44 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2424781991","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2424781991","pubTimestamp":1712144640,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"ARCA biopharma has struck a deal to combine with privately held biotechnology company Oruka Therapeutics in an all-stock reverse merger.ARCA on Wednesday said its shareholders would own about 2.38% of the combined company, while Oruka investors would own roughly 97.6%.ARCA, based in Westminster, Colo., said it also expects to pay a dividend of about $20 million to its shareholders  immediately prior to the closing of the deal, slated for the third quarter.A reverse merger allows a private company to go public by merging with a public one at a lower cost than is involved in traditional initial public offerings.ARCA said the combined company, which will operate under the Oruka Therapeutics name and trade under the symbol ORKA, will focus on advancing Oruka's portfolio of biologics targeting chronic skin diseases.ARCA said Oruka has struck a deal for a pre-closing private financing of around $275 million that would give the combined company a runway to fund its operations through 2027.Tra","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LENZ":"Therapeutics"},"translate_title":"ARCA Biopharma与Oruka Therapeutics达成反向合并协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABIO":0.9,"LENZ":1},"content_text":"By Colin Kellaher \n\n\n \n\n\n  ARCA biopharma has struck a deal to combine with privately held biotechnology company Oruka Therapeutics in an all-stock reverse merger. \n\n\n  ARCA on Wednesday said its shareholders would own about 2.38% of the combined company, while Oruka investors would own roughly 97.6%. \n\n\n  ARCA, based in Westminster, Colo., said it also expects to pay a dividend of about $20 million to its shareholders  immediately prior to the closing of the deal, slated for the third quarter. \n\n\n  A reverse merger allows a private company to go public by merging with a public one at a lower cost than is involved in traditional initial public offerings. \n\n\n  ARCA said the combined company, which will operate under the Oruka Therapeutics name and trade under the symbol ORKA, will focus on advancing Oruka's portfolio of biologics targeting chronic skin diseases. \n\n\n  ARCA said Oruka has struck a deal for a pre-closing private financing of around $275 million that would give the combined company a runway to fund its operations through 2027. \n\n\n  Trading in shares of ARCA, which closed Tuesday at $1.71, was halted premarket on Wednesday. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 03, 2024 07:44 ET (11:44 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}